Because inhibition of UBE2C promotes autophagic cell death in glioma cells, the FOXM1/UBE2C axis could be essential in developing resistance to therapies, and its targeting holds therapeutic value [79]. This evidence concerns the gene FOXM1 and central nervous system cancer.